Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Rule 8.3- Angle Plc

19 Jun 2008 11:37

RNS Number : 0870X
Henderson Global Investors Ltd
19 June 2008
 

FORM 8.3

DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE

(Rule 8.3 of the City Code on Takeovers and Mergers)

 

1. KEY INFORMATION

Name of person dealing (Note 1)

Henderson Global Investors Ltd

Company dealt in

Angle

Class of relevant security to which the dealings being disclosed relate (Note 2)

ORD GBP0.10

Date of dealing

18/06/08

 

2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE

 

(a)

Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 

 

Long

Short

 

Number 

(%)

Number

(%)

(1) Relevant securities 

295,000

1.0872

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

Total

295,000

1.0872

 

(b)

Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

 Class of relevant security:

Long

Short

 

Number

(%)

Number

(%)

(1) Relevant securities 

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

Total

 

(c) Rights to subscribe (Note 3)

 

Class of relevant security:

Details

3. DEALINGS (Note 4)

 

(a) Purchases and sales

 

Purchase/sale 

Number of securities

Price per unit (Note 5)

Sale

25,000

0.36 GBP

(b) Derivatives transactions (other than options)

 

Product name, e.g CFD

Long/short (Note 6)

Number of securities (Note 7)

Price per unit (Note 5)

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

 

Product name,e.g. call option 

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price 

Type, e.g. American, European etc.

Expiry date

Option moneypaid/received per unit (Note 5) 

 

 

(ii) Exercising

 

Product name, e.g. call option

Number of securities 

Exercise price per unit (Note 5)

 

(d) Other dealings (including new securities) (Note 4)

 

Nature of transaction (Note 8) 

Details

Price per unit (if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

……………………………………………………………………

……………………………………………………………………

Is a Supplemental Form 8 attached? (Note 9) NO

 

 

Date of disclosure

19 June 2008

Contact name

Barbara Menegazzi

Telephone number

020 7818 6492

If a connected EFM, name of offeree/offeror with which connected

N/A

If a connected EFM, state nature of connection (Note 10)

N/A

Notes

The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk

SUPPLEMENTAL FORM 8

 

 

DETAILS OF OPEN POSITIONS 

(This form should be attached to Form 8.1, Form 8.1(b)(ii) or Form 8.3, as appropriate)

 

 

 

 

OPEN POSITIONS (Note 1)

 

Product name,e.g. call option

 

Written or purchased

 

Number of securities to which the option or derivative relates

Exercise price (Note 2)

 

Type, e.g. American, European etc.

Expiry date

 

Notes

 

1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell should also be given on this form.

 

2. For all prices and other monetary amounts, the currency must be stated.

 

For details of the Code's dealing disclosure requirements, see Rule 8 and its Notes which can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RETEAEKNFDLPEFE
Date   Source Headline
4th Jan 20177:00 amRNSNotice of Results
28th Nov 20167:00 amRNSISSUE OF SHARE OPTIONS
24th Nov 20162:48 pmRNSResult of GM
4th Nov 20167:00 amRNSBarts Research Supports Potential Use of Parsortix
1st Nov 20167:00 amRNSNotice of GM
27th Oct 20167:00 amRNSDirector's share purchase
7th Oct 201611:57 amRNSHolding(s) in Company
4th Oct 20164:35 pmRNSResult of AGM
30th Sep 20167:00 amRNSResearch published in Clinical Chemistry
19th Sep 201611:14 amRNSIssue of Equity
9th Sep 20164:12 pmRNSAnnual Report and Accounts and Notice of AGM
4th Aug 20167:00 amRNSMD Anderson Cancer Center poster presentation
2nd Aug 20163:37 pmRNSEdison issues ADR update on Angle
28th Jul 20167:00 amRNSUse of Parsortix in GANNET53 drug trial
28th Jul 20167:00 amRNSPreliminary Results
27th Jul 20167:00 amRNSInitiation of 200 patient US ovarian cancer study
19th Jul 20167:00 amRNSInitiation of European ovarian cancer study
15th Jul 20167:00 amRNSNotice of Results
15th Jul 20167:00 amRNSParsortix gaining traction at EACR Conference
1st Jun 20163:04 pmRNSHolding(s) in Company
31st May 20164:36 pmRNSHolding(s) in Company
27th May 20163:12 pmRNSEdison issues research update on Angle
25th May 20167:00 amRNSCancer Research UK Contract
25th May 20167:00 amRNSPlacing
29th Apr 20167:00 amRNSNEW PUBLICATIONS UTILISING PARSORTIX
19th Apr 201612:43 pmRNSEdison issues research update on Angle
18th Apr 20167:00 amRNSParsortix potential in metastatic breast cancer
21st Mar 201612:12 pmRNSEdison issues research update on Angle
21st Mar 20167:00 amRNSParsortix potential for prostate cancer detection
9th Mar 20167:00 amRNSEuropean patent grant for Parsortix
28th Jan 20167:00 amRNSInterim Results
27th Jan 201610:42 amRNSNotice of Interim Results
25th Jan 20167:00 amRNSUKE publishes evaluation of Parsortix
22nd Dec 20157:00 amRNSCompletion of Geomerics Transaction
15th Dec 20157:00 amRNSParsortix first commercial sales
10th Dec 20157:00 amRNSChange of FTSE Industry Classification Benchmark
30th Nov 20155:56 pmRNSHolding(s) in Company
17th Nov 20157:00 amRNSLung Cancer Research Publication
12th Nov 20152:17 pmRNSISSUE OF SHARE OPTIONS
14th Oct 20157:00 amRNSPatent Grant
30th Sep 20155:50 pmRNSResult of AGM
28th Sep 20157:00 amRNSOvarian cancer results
24th Sep 20157:00 amRNSProstrate cancer study published PLOS ONE Journal
9th Sep 20157:00 amRNSBREAST CANCER RESULTS PRESENTED AT CDX CONFERENCE
8th Sep 20153:54 pmRNSAnnual Report and Accounts and Notice of AGM
26th Aug 20151:48 pmRNSIssue of Equity and Total Voting Rights
23rd Jul 20157:00 amRNSFinal Results
20th Jul 20157:00 amRNSNotification of Preliminary Results
8th Jul 20157:00 amRNSAppointment Of Scientific Adviser
11th Jun 20157:00 amRNSBarts Prostate Cancer Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.